Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease.

IF 2.9 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medical Principles and Practice Pub Date : 2024-01-01 Epub Date: 2024-07-24 DOI:10.1159/000540534

Salman Al-Sabah, Irina Al-Khairi, Mohammad Jamal, Mohammad Qaddoumi, Fahad Alajmi, Jijin Kumar, Nermeen Abukhalaf, Preethi Cherian, Dhanya Madhu, Hossein Arefanian, Carol Dsouza, Nada Alam-Eldin, Abdullah AlSabagh, Ashraf Al Madhoun, Suleiman Al-Sabah, Fahd Al-Mulla, Mohamed Abu-Farha, Jehad Abubaker

{"title":"Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease.","authors":"Salman Al-Sabah, Irina Al-Khairi, Mohammad Jamal, Mohammad Qaddoumi, Fahad Alajmi, Jijin Kumar, Nermeen Abukhalaf, Preethi Cherian, Dhanya Madhu, Hossein Arefanian, Carol Dsouza, Nada Alam-Eldin, Abdullah AlSabagh, Ashraf Al Madhoun, Suleiman Al-Sabah, Fahd Al-Mulla, Mohamed Abu-Farha, Jehad Abubaker","doi":"10.1159/000540534","DOIUrl":null,"url":null,"abstract":"Objectives: Bariatric surgery is a well-established treatment for obesity and type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.Methods: Rats were divided into surgery, semaglutide, and tirzepatide treatment groups, along with a control group (sham). Weight, oral glucose tolerance, and levels of metabolic markers were assessed, along with adipose and liver tissue analysis.Results: Surgery led to a 15.5% weight reduction, while rats treated with semaglutide exhibited a 10.7% reduction. Tirzepatide treatment at various concentrations (10, 50, and 100 nmol/kg) resulted in weight reductions of 5.0%, 14.9%, and 17.7%, respectively, compared to the sham group. Metabolic analyte levels decreased in intervention groups compared to the sham group, indicating improved metabolic health and glucose tolerance. Adipose tissue weight and hepatic liver fat droplets decreased in the intervention groups.Conclusion: Bariatric surgery and tirzepatide treatment significantly improved metabolic parameters in obese rats. Tirzepatide, particularly at higher concentrations, showed pronounced improvements compared to surgery and semaglutide. These findings suggest that high doses of tirzepatide could be explored as an alternative to bariatric surgery for the treatment of obesity.","PeriodicalId":18455,"journal":{"name":"Medical Principles and Practice","volume":" ","pages":"478-490"},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460980/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Principles and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540534","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Bariatric surgery is a well-established treatment for obesity and type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.

Methods: Rats were divided into surgery, semaglutide, and tirzepatide treatment groups, along with a control group (sham). Weight, oral glucose tolerance, and levels of metabolic markers were assessed, along with adipose and liver tissue analysis.

Results: Surgery led to a 15.5% weight reduction, while rats treated with semaglutide exhibited a 10.7% reduction. Tirzepatide treatment at various concentrations (10, 50, and 100 nmol/kg) resulted in weight reductions of 5.0%, 14.9%, and 17.7%, respectively, compared to the sham group. Metabolic analyte levels decreased in intervention groups compared to the sham group, indicating improved metabolic health and glucose tolerance. Adipose tissue weight and hepatic liver fat droplets decreased in the intervention groups.

Conclusion: Bariatric surgery and tirzepatide treatment significantly improved metabolic parameters in obese rats. Tirzepatide, particularly at higher concentrations, showed pronounced improvements compared to surgery and semaglutide. These findings suggest that high doses of tirzepatide could be explored as an alternative to bariatric surgery for the treatment of obesity.

查看原文本刊更多论文

双重 GLP-1/GIP 受体激动剂（替泽帕肽）与减肥手术对体重减轻和非酒精性脂肪肝的影响

目的：减肥手术是治疗肥胖症和 2 型糖尿病的一种行之有效的方法。作为一种双重 GIP/GLP-1 受体激动剂，替扎帕肽已成为一种治疗 2 型糖尿病的有前途的疗法。本研究旨在比较减肥手术、semaglutide（一种GLP-1受体激动剂）和替泽帕肽对以高脂肪饮食喂养的Sprague-Dawley大鼠的影响：将大鼠分为手术组、塞马鲁肽组和替泽帕特治疗组，以及对照组（假）。评估体重、口服葡萄糖耐量、代谢标志物水平以及脂肪和肝脏组织分析：结果：手术导致大鼠体重下降了 15.5%，而使用塞马鲁肽治疗的大鼠体重下降了 10.7%。与假体组相比，不同浓度（10、50 和 100 nmol/kg）的替泽帕肽治疗可使体重分别减少 5.0%、14.9% 和 17.7%。与假体组相比，干预组的代谢分析物水平有所下降，表明代谢健康和葡萄糖耐量得到改善。干预组的脂肪组织重量和肝脏脂肪滴均有所减少：结论：减肥手术和替哌肽治疗可明显改善肥胖大鼠的代谢指标。与手术和塞马鲁肽相比，替扎帕肽（尤其是高浓度替扎帕肽）能明显改善肥胖大鼠的代谢指标。这些研究结果表明，高剂量的替唑帕肽可作为减肥手术的替代疗法，用于治疗肥胖症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Principles and Practice 医学-医学：内科

CiteScore

6.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Medical Principles and Practice'', as the journal of the Health Sciences Centre, Kuwait University, aims to be a publication of international repute that will be a medium for dissemination and exchange of scientific knowledge in the health sciences.